Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recently Approved and Upcoming Treatments for Narcolepsy
Michael J. Thorpy
CNS Drugs (2020) Vol. 34, Iss. 1, pp. 9-27
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

Photocatalytic defluoroalkylation and hydrodefluorination of trifluoromethyls using o-phosphinophenolate
Can Liu, Ni Shen, Rui Shang
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 106
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation
Chuan Hong, Noel Byrne, Beata Zamlynny, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 104
Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients
Rebecca Evans, Haruhide Kimura, Robert Alexander, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 35
Open Access | Times Cited: 57
Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study
Rami Ben‐Joseph, Ragy Saad, Jed Black, et al.
SLEEP (2023) Vol. 46, Iss. 10
Open Access | Times Cited: 25
Narcolepsy: Beyond the Classic Pentad
Anne Marie Morse, Sooyoung Kim, Shelby Freedman Harris, et al.
CNS Drugs (2025)
Open Access | Times Cited: 1
Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial
Lois E. Krahn, Asim Roy, John W. Winkelman, et al.
CNS Drugs (2025)
Open Access | Times Cited: 1
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
Clete A. Kushida, Colin M. Shapiro, Thomas Roth, et al.
SLEEP (2021) Vol. 45, Iss. 6
Open Access | Times Cited: 43
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
Thomas Roth, Yves Dauvilliers, Michael J. Thorpy, et al.
CNS Drugs (2022) Vol. 36, Iss. 4, pp. 377-387
Open Access | Times Cited: 23
TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy
Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 385, Iss. 3, pp. 193-204
Open Access | Times Cited: 16
Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019
Zizhen Yin, Wenfei Hu, Wei Zhang, et al.
Amino Acids (2020) Vol. 52, Iss. 9, pp. 1227-1261
Closed Access | Times Cited: 39
<p>Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns</p>
Emily C. Barker, Julie Flygare, Shalini Paruthi, et al.
Nature and Science of Sleep (2020) Vol. Volume 12, pp. 453-466
Open Access | Times Cited: 35
The Orexin receptors: Structural and anti-tumoral properties
Alain Couvineau, Pascal Nicole, Valérie Gratio, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 20
Solriamfetol improves chronic sleep fragmentation-induced increases in sleep propensity and ameliorates explicit memory in male mice
C. Puech, Mohammad Badran, Max B. Barrow, et al.
SLEEP (2023) Vol. 46, Iss. 5
Open Access | Times Cited: 12
Expanding the Use of Benzothioxanthene Imides to Photochemistry: Eco‐Friendly Aerobic Oxidation of Sulfides to Sulfoxides
Stamatis K. Serviou, Petros L. Gkizis, Darío Puchán Sánchez, et al.
ChemSusChem (2024)
Open Access | Times Cited: 4
Comments on: The Utility of Betahistine Dihydrochloride, a Structural Analog of Histamine, in Clozapine-Associated Daytime Sedation: A Case Series
Singh Ajay, Diveesha Munipati, Sai Krishna Tikka
Indian Journal of Psychological Medicine (2025)
Open Access
New nanomanufacturing strategy through bioinspired design, for promising treatment of Parkinson’s disease
Aliaa A. Razzak, Zahraa S. Al‐Garawi, Adawiya J. Haider, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Parishin A alleviates insomnia by regulating hypothalamic-pituitary-adrenal axis homeostasis and directly targeting orexin receptor OX2
Lijing Zhang, Ya-Ru Zhao, Liqiao Chen, et al.
European Journal of Pharmacology (2025), pp. 177498-177498
Closed Access
Case Report: Narcolepsy patients masked behind obstructive sleep apnea syndrome (OSAS): report of 2 cases and literature review
Simin Zou, Xiaomei Zhang, Yinping Shen, et al.
Frontiers in Neuroscience (2025) Vol. 19
Open Access
Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model
Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 220, pp. 173464-173464
Open Access | Times Cited: 18
Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression
Andrew D. Krystal, Ruth M. Benca, Russell Rosenberg, et al.
Journal of Psychiatric Research (2022) Vol. 155, pp. 202-210
Open Access | Times Cited: 17
Tetrad of Narcolepsy Type 1: Treatment and Management
Kanishka Gandhi, Suraiya Ferdous
Cureus (2024)
Open Access | Times Cited: 3
Schisandrin B exerts hypnotic effects in PCPA‑treated rats by increasing hypothalamic 5‑HT and &gamma;‑aminobutyric acid levels
Mengyang Wang, Ning Li, Shu Jing, et al.
Experimental and Therapeutic Medicine (2020) Vol. 20, Iss. 6
Open Access | Times Cited: 24
The development of sleep/wake disruption and cataplexy as hypocretin/orexin neurons degenerate in male vs. female Orexin/tTA; TetO-DTA Mice
Yu Sun, Ryan K. Tisdale, Sunmee Park, et al.
SLEEP (2022) Vol. 45, Iss. 12
Open Access | Times Cited: 14
Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis
Shuqin Zhan, Hui Ye, Ning Li, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 217-230
Open Access | Times Cited: 8
Connexins as therapeutic targets in neurological and neuropsychiatric disorders
Mathieu Charvériat, Franck Mouthon, W. Rein, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1867, Iss. 5, pp. 166098-166098
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top